Bispecific TRBC Molecules for Selective T Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for T cell cancers face challenges in selectively targeting malignant T cells without depleting healthy T cells, leading to immunosuppression, as T cell cancers express similar surface antigens as normal T cells, making it difficult to develop targeted therapies that spare healthy cells.
Innovation Solution
Development of bispecific molecules that target specific subsets of T cell receptor β chain constant regions (TRBC) to selectively deplete malignant T cells while sparing healthy T cells, using antibodies or antibody drug conjugates that bind to TRBC1 or TRBC2 polypeptides, allowing for the preservation of approximately half of the normal T cells to maintain immune function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If targeted immunotherapeutic agents are used to deplete T cells expressing pan-T cell antigens, then T cell cancers can be treated, but healthy T cells are depleted leading to immunosuppression
Solution Approach 1:
The patent segments the T cell population by targeting specific TRBC isoforms (TRBC1 or TRBC2) that are differentially expressed on cancerous versus healthy T cells. By dividing the T cell antigen landscape into distinct targets, the therapy can selectively eliminate cancer cells while preserving healthy T cells expressing the alternative TRBC isoform.
Solution Approach 2:
The patent applies local quality by creating T cell subsets with different antigen expression profiles. Cancerous T cells are engineered to express only one TRBC isoform (either TRBC1 or TRBC2), while healthy T cells express a mixture of both. The immunotherapeutic agent targets the specific TRBC isoform present on cancer cells, creating localized specificity that spares healthy cells.
2Productivity
If pan-T cell antigens are targeted for therapy, then T cell cancers can be eliminated, but the resultant T cell depletion leads to clinically unacceptable immunosuppression
Solution Approach 1:
The therapy segments the T cell antigen repertoire by exploiting the binary expression pattern of TRBC1/TRBC2 on cancer cells versus the mixed expression on healthy cells. This segmentation allows selective targeting of cancer cells expressing one specific TRBC isoform while leaving healthy cells expressing the other isoform intact.
Solution Approach 2:
The patent changes the targeting parameter from pan-T cell antigens (which are universally expressed) to specific TRBC isoforms (which show differential expression patterns). This parameter change enables selective recognition of cancer cells based on their unique TRBC expression profile while preserving healthy T cells with different TRBC profiles.
3Productivity
If bispecific molecules target TRBC1 polypeptide, then TRBC1+ cancerous T cells are depleted, but healthy TRBC1+ T cells are also depleted
Solution Approach 1:
The patent exploits the local quality difference in TRBC expression between cancer and healthy T cells. While both cell types may express TRBC1, cancer cells exclusively express TRBC1 while healthy cells co-express both TRBC1 and TRBC2. The bispecific molecule targets TRBC1, and the selective depletion occurs because healthy TRBC2+ cells (which co-express TRBC2) are spared, maintaining a functional T cell population.
Solution Approach 2:
The patent uses TRBC2 as an intermediary marker for healthy T cell preservation. By targeting TRBC1 while relying on the presence of TRBC2 to identify and spare healthy cells, the therapy creates a built-in mechanism for selective depletion. The TRBC2 polypeptide acts as a protective marker that prevents depletion of healthy T cells even when they co-express TRBC1.
Data Source
AI summary
This document relates to methods and materials for treating T cell cancers. For example, a composition containing one or more bispecific molecules targeting T cell receptor £ chain constant region (TRBC) can be administered to a mammal having a T cell cancer to treat the mammal. For example, this document provides methods and materials for using one or more bispecific molecules to treat a mammal having a T cell cancer.